NL-OMON45475已完成4 期
Pharmacokinetics of posaconazole given as a single intravenous dose to obese subjects: Dosing Obese with Noxafil® Under a Trial (DONUT). - DONUT
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64(—)
入选标准
- •1. Subjects BMI:
- •o obese groups: subject must have a BMI >=35 kg/m2 at the time of inclusion,
- •o non-obese group: subject must have a BMI >=18.5 and < 25kg/m2 at the time of inclusion.;2. Subject is at least 18 years of age on the day of screening and not older than 65 years of age on the day of dosing;
- •3. If a woman, is neither pregnant nor able to become pregnant and is not nursing an infant;;4. Subject is able and willing to sign the Informed Consent before screening evaluations.
- •For the non-obese subjects the following additional inclusion criteria applies:
- •5. Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, hematology and urinalysis testing within 6 weeks prior to study drug administration. Results of biochemistry, hematology and urinalysis testing should be within the laboratory's reference ranges (see Appendix A). If laboratory results are not within the reference ranges, the subject is included based on the investigator*s judgment that the observed deviations are not clinically relevant. This should be clearly recorded;
排除标准
- •1. Documented history of sensitivity to medicinal products or excipients similar to those found in the posaconazole preparation;
- •2. History of, or known abuse of drugs, alcohol or solvents (up until a maximum of three months before study drug administration);
- •3. Use of medication that has known relevant interaction with study drug as determined by the investigator up to 1 weeks prior to study drug administration.
- •4. Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks prior to study drug administration;
- •5. Blood transfusion within 8 weeks prior to study drug administration;
- •6. Any other sound medical, psychiatric and/or social reason as determined by the investigator.
研究者
相似试验
进行中(未招募)
不适用
A Study to Look at the Way the Body Absorbs and Distributes Posaconazole in the Blood and Lungs of Lung Transplant Recipients (PAPAL Study)Invasive fungal infection (IFI) in lung transplant patients with and without cystic fibrosis.MedDRA version: 15.0Level: PTClassification code 10049085Term: Antifungal prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-003140-68-GBMSD40
进行中(未招募)
1 期
Exposure to posaconazole given intravenous compared to oral.EUCTR2016-001182-87-NLRadboud University Medical Centre27
进行中(未招募)
1 期
Exposure to posaconazole given intravenous compared to oral.EUCTR2016-001182-87-BERadboud University Medical Centre27
已完成
4 期
Dosing Obese With Noxafil® Under a Trial (DONUT)Morbid ObesityNCT03246386Radboud University Medical Center24
已完成
不适用
Pharmacokinetic Evaluation of POSaconazole boosted Fosamprenavir (EPOS)HIVhuman immunodeficiency virus10017528NL-OMON32580niversitair Medisch Centrum Sint Radboud24
